Abstract: Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.

Abstract: The present disclosure provides devices for delivery of powder formulations and methods of manufacture and use of such devices.

Abstract: [Problem] To provide a urine scattering prevention device which does not give off a foul smell even when used, and which is easy to replace. [Solution] A urine scattering prevention device 1 includes a urine receiving portion 5 disposed in a urinal 3, and a leg portion 7 which supports the urine receiving portion 5 vertically upward.

Abstract: A nozzled cartridge (20) for storing medicine, according to an aspect of the present application, includes a medicine container (21) that is to be filled with a predetermined quantity of a powdered medicine, a nozzle portion (22) that is formed on the medicine container (21) and that ejects the powdered medicine, a closing member (24) that closes an opening (22a) in the nozzle portion (22), and a valve member (25) that functions as a plug to close another opening (23a) in the medicine container (21), and that is opened when administering medicine. The nozzled cartridge (20) is detachably mountable to a sprayer (30) when administering medicine.

Abstract: [Problem] To provide a mass spectrometry method that uses a chromatography-mass spectrometry device, wherein mass spectrometry can be performed with a convenient method at low cost. [Solution] A mass spectrometry method for a target object, using a chromatography-mass spectrometry device that includes, in order, a chromatograph, an ionization unit, a first mass separation unit, a collision cell, a second mass separation unit, and an ion detection unit, wherein an ion pair agent and Hünig's base are added to a mobile phase of the chromatograph, and the absolute value of an applied voltage of the collision cell is 20V to 250V.

Abstract: Provided herein are vaccine compositions for example in a dry powder form for intranasal delivery, and their preparation methods. Also provided are methods of using vaccine compositions, for example in stimulating mucosal or systemic immune responses by delivering the vaccine compositions intranasally.

Abstract: A device according to one aspect of the present invention is an intranasal powdered medicine dispensing device (10) for dispensing a predetermined dose of a powdered medicine into a nasal cavity. The device includes a nozzle member (20) that includes a filling space (22) for a powdered medicine (M) and an ejection opening (26) for the powdered medicine (M), a closing member that closes the ejection opening (26), a sealing member (40) that seals an opening (24) of the filling space (22), an injection pump member (50) that sends out air, as the injection pump member contracts, to eject the powdered medicine from the ejection opening (26), a puncturing member (60) that moves, as the injection pump member (50) contracts, and forms a hole by puncturing in the sealing member (40) while moving, and a guide member (70) that restricts the puncturing member (60) from moving in a direction perpendicular to the direction of the movement thereof.

Abstract: [Problem] To enable a person intended by a chairperson to be effectively determined as a speaker by matching the hand-raising of the speaker and an indicating direction of the chairperson, and turning ON only a microphone of the matched speaker. [Solution] Provided is a conference support system including: a plurality of voice input means which receive voices as an input; a plurality of ON/OFF control means which control the plurality of voice input means to be respectively turned ON/OFF and which respectively correspond to the plurality of voice input means; a hand-raising recognition means which recognizes hand-raising positions of participants, which respectively corresponds to the plurality of voice input means; a designated direction recognition means which recognizes a direction designated by a specified person.

Abstract: [Problem] To provide an enclosure that can be easily cleaned, [Solution] A fish-breeding enclosure including: a frame 3 constituting the sides of a cuboid; a first net 11 covering a right side surface 5, a bottom surface 7, and a left side surface 9 of the frame 3; a first net feeder 19 for feeding the first net 11 and a second net 17 that covers a front surface 13, the bottom surface 7, and a rear surface 15 of the frame 3; and a second net feeder 21 for feeding the second net 17. When the first net 11 or the second net 17 is renewed. the first net 11 or the second net 17 is drawn out from the first net feeder 19 or the second net feeder 21, respectively.

Abstract: Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.

Abstract: A nozzled cartridge (20) for storing medicine, according to an aspect of the present application, includes a medicine container (21) that is to be filled with a predetermined quantity of a powdered medicine, a nozzle portion (22) that is formed on the medicine container (21) and that ejects the powdered medicine, a closing member (24) that closes an opening (22a) in the nozzle portion (22), and a valve member (25) that functions as a plug to close another opening (23a) in the medicine container (21), and that is opened when administering medicine. The nozzled cartridge (20) is detachably mountable to a sprayer (30) when administering medicine.

Abstract: Anguilliformes breeding water contains a thyroid hormone such as thyroxine, and a method for rearing anguilliformes includes a step for administering a thyroid hormone such as thyroxine, wherein the amount of the thyroid hormone to be administered changes as the anguilliforme fingerling changes from a transformation start phase (stage 1) to a transformation final phase (stage 2), and the amount of the thyroid hormone to be administered in the transformation final phase (stage 2) is less than the amount of the thyroid hormone to be administered in the transformation start phase (stage 1).

Abstract: Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.

Abstract: Problem To provide a chiral nucleic acid adjuvant and anti-allergic agent having anti-allergic effect. Solution An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.

Abstract: [Subject] A test substance application system for animal experiment capable of administering a required amount of a test substance uniformly and reliably from a nose or a mouth into a nasal cavity or into a lung of an experimental animal is provided. [Means for Solution] The system includes a respiration monitoring device 2 that monitors a respiration state of an experimental animal detected by a respiration pick-up device 1 to thereby measure a timing upon switching from an expiratory phase to an inhalatory phase and outputs a trigger signal T at that timing, and an application device 3 that sprays a predetermined amount of a test substance into a nasal cavity or an oral cavity of the experimental animal when the trigger signal T is outputted from the device 2.

Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance.

Abstract: Summary Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. Solution The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acid at 3? end and 5? end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.

Abstract: To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an imidazo[1,2-a]pyridine derivative, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

Abstract: Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5?-X1CpG X2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.

Abstract: Devices for delivery of dry powder formulations are also provided. Devices can be single-use devices. Formulations and methods of manufacture are provided for dry powder compositions suitable for intranasal administration. Also provided are methods of use for preventing or controlling emesis and other diseases and disorders and devices, compositions, and methods for nasal delivery of therapeutic formulations.